ArticleJournal of the International Neuropsychological Society : JINS2026
Cognitive workload and its relationship with neurocognitive performance before and after breast cancer chemotherapy.
Article in Journal of the International Neuropsychological Society : JINS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04033419 (Memantine for Prevention of Cognitive Decline During Adjuvant or Neoadjuvant Chemotherapy in Patients With Breast Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Memantine for Prevention of Cognitive Decline During Adjuvant or Neoadjuvant Chemotherapy in Patients With Breast Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo compare associations between neurocognitive testing and two different self-report paradigms: (1) recall-based (PROMIS Cognitive Function) and (2) real-time, task-specific (NASA-Task Load Index [NASA-TLX]) among 56 patients with breast cancer.
methodsThis is a secondary analysis from a phase II, single-arm trial of memantine to prevent cognitive decline among patients receiving chemotherapy for breast cancer (NCT04033419). Before chemotherapy and 4 weeks after their final cycle, participants completed neuropsychological assessment and self-report measures. Memantine was administered between assessments. At pre-chemotherapy, multivariable linear regression evaluated associations between a unit-weighted, composite neurocognitive test score with PROMIS Cognitive Function and NASA-TLX, controlling for age, cancer stage, and cognitive reserve. Explanatory analyses examined associations within individual neurocognitive subtests. Multivariable regression explored the extent to which pre-treatment self-reported cognition predicted post-treatment performance.
resultsPre-chemotherapy, higher NASA-TLX scores (greater perceived workload) were robustly associated with worse performance (
conclusionsThe NASA-TLX and neurocognitive performance were strongly associated, particularly in the executive function domain. Future work involving the NASA-TLX in cancer populations, including its use in everyday contexts, will help clarify whether it may enhance CRCI characterization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.